Verastem (VSTM) Competitors

Celldex Therapeutics (NASDAQ:CLDX) and Verastem (NASDAQ:VSTM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.

Which has more risk and volatility, CLDX or VSTM?

Celldex Therapeutics has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500. Comparatively, Verastem has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500.

Do analysts prefer CLDX or VSTM?

Celldex Therapeutics presently has a consensus target price of $51.75, suggesting a potential upside of 107.50%. Verastem has a consensus target price of $13.29, suggesting a potential upside of 71.87%. Given Celldex Therapeutics' higher possible upside, equities research analysts clearly believe Celldex Therapeutics is more favorable than Verastem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.89
Verastem	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is CLDX or VSTM more profitable?

Verastem has a net margin of 0.00% compared to Celldex Therapeutics' net margin of -3,446.88%. Celldex Therapeutics' return on equity of -27.61% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	-3,446.88%	-27.61%	-26.20%
Verastem	N/A	-2,003.62%	-119.85%

Do institutionals & insiders hold more shares of CLDX or VSTM?

88.4% of Verastem shares are held by institutional investors. 4.4% of Celldex Therapeutics shares are held by insiders. Comparatively, 2.1% of Verastem shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Does the media refer more to CLDX or VSTM?

In the previous week, Verastem had 14 more articles in the media than Celldex Therapeutics. MarketBeat recorded 18 mentions for Verastem and 4 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 0.49 beat Verastem's score of 0.45 indicating that Celldex Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Verastem	2 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has preferable earnings and valuation, CLDX or VSTM?

Verastem has lower revenue, but higher earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$7.02M	235.94	-$157.86M	-$3.01	-8.29
Verastem	$10K	47,570.42	-$130.64M	-$3.28	-2.36

Summary

Celldex Therapeutics beats Verastem on 9 of the 17 factors compared between the two stocks.